Home › NDC Lookup › RxCUI directory › RxCUI 2572293

0.4 ML cyclosporine 0.5 MG/ML Ophthalmic Suspension [Restasis] — RxCUI 2572293

RxNorm drug concept · Semantic branded drug
RxCUI 2572293 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2572293
Official name0.4 ML cyclosporine 0.5 MG/ML Ophthalmic Suspension [Restasis]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as0.4 ML Restasis 0.5 MG/ML Ophthalmic Suspension; Restasis 0.05 % in 0.4 ML Ophthalmic Emulsion; Restasis 0.05 % per 0.4 ML Ophthalmic Suspension
FDA products mapped2
Package NDCs mapped4
Reported Medicaid activity (SDUD)280,762 prescriptions · 45 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Cyclosporine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Cyclosporine levels in your blood can vary quite a bit, and both too much and too little can cause real problems — too high raises the risk of kidney damage, and too low means the...
  • Why do I need blood tests so often while taking cyclosporine?
  • No — grapefruit and grapefruit juice are a hard no with cyclosporine. They block a key enzyme in your body that normally clears cyclosporine, which can cause your blood levels to c...
  • Can I eat grapefruit while taking cyclosporine?
📖 Read our full Cyclosporine guide →

🕸️ Concept Web — How 0.4 ML cyclosporine 0.5 MG/ML Ophthalmic Suspens... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 0.4 ML cyclosporine 0.5 MG/ML Ophthalmic Suspension [Restasis] RxCUI 2572293

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Cyclosporine 3008
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Restasis 352951
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Cyclosporine Ophthalmic Suspension 378766
    • Cyclosporine Ophthalmic Product 1156187
    • Cyclosporine Ophthalmic Suspension [Restasis] 402330
    • Restasis Ophthalmic Product 1182527
    • Ophthalmic Suspension 316964
    • Ophthalmic Product 1151135
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Cyclosporine 0.5 MG/ML [Restasis] SBDC · 576100
  • Cyclosporine Ophthalmic Suspension [Restasis] SBDF · 402330
  • Restasis Ophthalmic Product SBDG · 1182527
  • Restasis BN · 352951

📦 FDA Products & Package NDCs

2 products · 4 package NDCs
4 package NDCs map to RxCUI 2572293 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00023-9163-12 5 VIAL, SINGLE-USE in 1 CARTON (0023-9163-12) / .4 mL in 1... RESTASIS Allergan, Inc. 2003-04-01
00023-9163-30 30 VIAL, SINGLE-USE in 1 TRAY (0023-9163-30) / .4 mL in 1 V... RESTASIS Allergan, Inc. 2003-04-01
00023-9163-60 60 VIAL, SINGLE-USE in 1 TRAY (0023-9163-60) / .4 mL in 1 V... RESTASIS Allergan, Inc. 2003-04-01
50090-4476-00 30 VIAL, SINGLE-USE in 1 TRAY (50090-4476-0) / .4 mL in 1 V... RESTASIS A-S Medication Solutions 2019-08-26
Observed labelers: Allergan, Inc. (3) · A-S Medication Solutions (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$10.3169
Range $10.3159–$10.3179 · middle 50% $10.3164–$10.3174 · 2 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.